Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
Champions Oncology plans to release July 31, 2026 quarter results and hold an investor conference call with replay access on September 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Champions Oncology (CSBR) will report financial and operational results for the quarter ended July 31, 2026 on Thursday, September 10, 2026, after market close.
The company will host a conference call at 4:30 P.M. EDT (1:30 P.M. PDT). Participants can join via domestic dial-in 888-506-0062 or international 973-528-0011 using access code 938837. A replay will be available by phone and via the investors section of the company website.
Details
News Market Reaction – CSBR
On Sep 4, the day this news came out, CSBR closed 1.14% below the previous close.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Quarter End
- July 31, 2026
- First quarter
- Results Announcement
- September 10, 2026
- After market close
Previous Earnings date Reports
-
Scheduled fourth-quarter and year-end results after market close
-
Scheduled third-quarter results and conference call after market close
-
Scheduled second-quarter financial and operational results after market close
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
patient-derived xenograft medical
in vivo technical
ex vivo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 938837. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 54523, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.